Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

July 2013

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Aqueous Flare and Choroidal Thickness in Patients with Chronic Hepatitis C Virus Infection: A Pilot Study. Strobbe E, Cellini M, Campos EC. Ophthalmology. 2013 Jun 3. pii: S0161-6420(13)00325-4. doi: 10.1016/j.ophtha.2013.03.040. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23743439

 

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection. Abe H, Aida Y, Ishiguro H, et al. J Med Virol. 2013 Jun 17. doi: 10.1002/jmv.23626. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23775277

 

Telaprevir Activity in Treatment-Naive Genotype 4 Hepatitis C-Infected Patients: A Randomized Trial. Benhamou Y, Moussalli J, Ratziu V, et al. J Infect Dis. 2013 Jun 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23801602

 

Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. Dai CY, Yeh ML, Huang CF, et al. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12313. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23808794

 

Occupational Exposure to Hepatitis C Virus: Early T-Cell Responses in the Absence of Seroconversion in a Longitudinal Cohort Study. Heller T, Werner JM, Rahman F, et al. J Infect Dis. 2013 Jun 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23801608

 

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Sulkowski MS, Bourlière M, Bronowicki JP, et al. Hepatology. 2013 Jun;57(6):2155-63. doi: 10.1002/hep.26386.

http://www.ncbi.nlm.nih.gov/pubmed/23504636

 

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Sulkowski MS, Asselah T, Lalezari J, et al. Hepatology. 2013 Jun;57(6):2143-54. doi: 10.1002/hep.26276.

http://www.ncbi.nlm.nih.gov/pubmed/23359516

 

Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Vera-Llonch M, Martin M, Aggarwal J, et al. Aliment Pharmacol Ther. 2013 Jul;38(2):124-33. doi: 10.1111/apt.12354. Epub 2013 Jun 3.

http://www.ncbi.nlm.nih.gov/pubmed/23725204

 

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Mauss S, Hueppe D, Alshuth U. Hepatology. 2013 Jun 28. doi: 10.1002/hep.26602. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23813604

 

Basic and Applied Science, Pre-Clinical Studies

 

Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected huh7 cultures. Bush CO, Greenstein AE, Delaney WE 4th, Beran RK. PLoS One. 2013 Jun 3;8(6):e65273. doi: 10.1371/journal.pone.0065273. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23755208

 

Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313-327 and 432-443 of Hepatitis C Virus E1E2 Glycoproteins.

Liu R, Rao H, Wang J, et al. PLoS One. 2013 Jun 24;8(6):e66872. doi: 10.1371/ journal.pone.0066872. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23826163

 

Upregulation of OX40 ligand on monocytes contributes to early virological control in patients with chronic hepatitis C. Zhang JY, Wu XL, Yang B, et al. Eur J Immunol. 2013 Jul;43(7):1953-62. doi: 10.1002/eji.201243097. Epub 2013 Jun 26.

http://www.ncbi.nlm.nih.gov/pubmed/23589118

 

Molecular simulations illuminate the role of regulatory components of the RNA polymerase from the hepatitis C virus in influencing protein structure and dynamics.

Davis BC, Thorpe IF. Biochemistry. 2013 Jul 2;52(26):4541-52. doi: 10.1021/bi400251g. Epub 2013 Jun 21.

http://www.ncbi.nlm.nih.gov/pubmed/23738897

 

Mutations in the STAT1 interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Anjum S, Afzal MS, Ahmad T, Aslam B, Waheed Y, Shafi T, Qadri I. Mol Med Rep. 2013 Aug;8(2):487-92. doi: 10.3892/mmr.2013.1541. Epub 2013 Jun 25.

http://www.ncbi.nlm.nih.gov/pubmed/23799612

 

A heterologous prime/boost vaccination-strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. Fournillier A, Frelin L, Jacquier E, et al. J Infect Dis. 2013 Jun 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23776192

 

 

 

HIV/HCV Coinfection

 

Histopathological findings of an uncommon co-infection: Echinococcus vogeli, HIV, hepatitis C virus, and hepatitis B virus. de Almeida FB, Corrêa CL, de Siqueira NG, et al. Int J Infect Dis. 2013 Jun 1. pii: S1201-9712(13)00170-7. doi: 10.1016/j.ijid.2013.04.002. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23735863

 

In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. Am J Clin Nutr. 2013 Jun 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23739141

 

Depression and Fatigue in Chronic Hepatitis C Patients with and Without HIV Co-Infection. Tavakkoli M, Ferrando SJ, Rabkin J, Marks K, Talal AH. Psychosomatics. 2013 Jun 4. pii: S0033-3182(13)00047-9. doi: 10.1016/j.psym.2013.02.009. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23756122

 

Microbial Translocation and Liver Disease Progression in Women Coinfected With HIV and Hepatitis C Virus. French AL, Evans CT, Agniel DM, et al. J Infect Dis. 2013 Jun 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23687224

 

Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. Keane C, O'Shea D, Reiberger T, et al. PLoS One. 2013 Jun 24;8(6):e66831. doi: 10.1371/journal.pone.0066831. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23826153

 

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Sulkowski M, Pol S, Mallolas J, et al. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

http://www.ncbi.nlm.nih.gov/pubmed/23768747

 

The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial. Chapplain JM, Bellissant E, Guyader D, et al. J Infect. 2013 Jun 22. pii: S0163-4453(13)00152-7. doi: 10.1016/j.jinf.2013.05.007. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23800784

 

Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers. Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, et al. J Acquir Immune Defic Syndr. 2013 Jun 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23797694

 

Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. Terrier B, Costagliola D, Prevot S, et al. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):249-53. doi: 10.1097/QAI.0b013e31828a77f0.

http://www.ncbi.nlm.nih.gov/pubmed/23403861

 

Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients. Funk EK, Shaffer A, Shivakumar B, et al. AIDS Res Hum Retroviruses. 2013 Jun 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23701022

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Moyer VA; on behalf of the U.S. Preventive Services Task Force*. Ann Intern Med. 2013 Jun 25. doi: 10.7326/0003-4819-159-5-201309030-00672. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23798026

 

Management of the extrahepatic symptoms of chronic hepatitis C: feasibility of a randomized controlled trial of exercise. McKenna O, Cunningham C, Gissane C, Blake C. Am J Phys Med Rehabil. 2013 Jun;92(6):504-12. doi: 10.1097/PHM.0b013e31828cd500.

http://www.ncbi.nlm.nih.gov/pubmed/23552336

 

HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA. Garfein RS, Rondinelli A, Barnes RF, et al. J Urban Health. 2013 Jun;90(3):516-28. doi: 10.1007/s11524-012-9728-0.

http://www.ncbi.nlm.nih.gov/pubmed/22766605

 

The role of attachment style and depression in patients with hepatitis C. Sockalingam S, Blank D, Jarad AA, Alosaimi F, Hirschfield G, Abbey SE. J Clin Psychol Med Settings. 2013 Jun;20(2):227-33. doi: 10.1007/s10880-012-9335-y.

http://www.ncbi.nlm.nih.gov/pubmed/23108508

 

Association of tattooing and hepatitis C virus infection: A multicenter case-control study.

Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Hepatology. 2013 Jun;57(6):2117-23. doi: 10.1002/hep.26245.

http://www.ncbi.nlm.nih.gov/pubmed/23315899

 

The epidemiology of hepatitis C in a Canadian Indigenous population. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. Can J Gastroenterol. 2013 Jun;27(6):340-39.

http://www.ncbi.nlm.nih.gov/pubmed/23781516

 

A Comparison of Enrollees Versus Non-enrollees in a Patient/Family HCV Psycho-education Study. Pollio DE, North CS, Hudson AM, Hong BA. J Clin Psychol Med Settings. 2013 Jun;20(2):156-63. doi: 10.1007/s10880-012-9332-1.

http://www.ncbi.nlm.nih.gov/pubmed/22990747

 

The AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. Hepatology. 2013 Jun 14. doi: 10.1002/hep.26578. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23775835

 

Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection?

Naing C, Mak JW, Wai N, Maung M. Curr Diab Rep. 2013 Jun;13(3):428-34. doi: 10.1007/s11892-013-0370-3.

http://www.ncbi.nlm.nih.gov/pubmed/23463119

 

Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study.

Jordan AE, Masson CL, Mateu-Gelabert P, et al. Harm Reduct J. 2013 Jun 20;10:10. doi: 10.1186/1477-7517-10-10.

http://www.ncbi.nlm.nih.gov/pubmed/23786800

 

Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. McGibbon E, Bornschlegel K, Balter S. Am J Med. 2013 Jun 17. pii: S0002-9343(13)00228-3. doi: 10.1016/j.amjmed.2013.01.031. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23786667

 

Patient perspectives on hepatitis C and its treatment. North CS, Devereaux R, Pollio DE, Hong BA, Jain MK. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23788155

 

Liver Cancer

 

Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B. AJR Am J Roentgenol. 2013 Jun;200(6):W610-6. doi: 10.2214/AJR.12.9151.

http://www.ncbi.nlm.nih.gov/pubmed/23701091

 

The insulin-like growth factor-1 and expression of its binding protein 3 in chronic hepatitis C and hepatocellular carcinoma. Adamek A, Kasprzak A, Mikoś H, et al. Oncol Rep. 2013 Jun 19. doi: 10.3892/or.2013.2546. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23784592

 

Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras. Baddour N, Farrag E, Zeid A, Bedewy E, Taher Y. Chin J Cancer Res. 2013 Jun;25(3):281-8. doi: 10.3978/j.issn.1000-9604.2013.04.02.

http://www.ncbi.nlm.nih.gov/pubmed/23825904

 

Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Aliment Pharmacol Ther. 2013 Aug;38(3):303-12. doi: 10.1111/apt.12370. Epub 2013 Jun 10.

http://www.ncbi.nlm.nih.gov/pubmed/23750991

 

Non-viral factors contributing to hepatocellular carcinoma. Hamed MA, Ali SA. World J Hepatol. 2013 Jun 27;5(6):311-22. doi: 10.4254/wjh.v5.i6.311.

http://www.ncbi.nlm.nih.gov/pubmed/23805355

 

Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. Chang ML, Lin YJ, Chang CJ, et al. PLoS One. 2013 Jun 21;8(6):e64891. Print 2013.

http://www.ncbi.nlm.nih.gov/pubmed/23805180

 

Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Quan H, Zhou F, Nie D, et al. Oncogene. 2013 Jun 17. doi: 10.1038/onc.2013.225. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23770846

 

A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Beard RE, Hanto DW, Gautam S, Miksad RA. Surgery. 2013 Jun 15. pii: S0039-6060(13)00071-8. doi: 10.1016/j.surg.2013.02.019. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23777589